Adding trastuzumab to carboplatin and paclitaxel improves overall survival in advanced-stage HER2/NEU overexpressing uterine serous carcinoma or carcinosarcoma

被引：0
|
作者：
Lu, Ting-Fang [1 ]
Lou, Sun [1 ]
Shih, Yu-Hsiang [1 ]
Chen, Yen-Fu [1 ]
Fan, Chun Ting [1 ]
Wang, Shao-Jing [1 ]
Hsu, Shih-Tien [1 ]
Liu, Chin-Ku [1 ]
Hwang, Sheau-Feng [1 ]
Lu, Chien-Hsing [1 ]
机构：
[1] Taichung Vet Gen Hosp, Obstet & Gynecol Dept, Taichung, Taiwan
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2024年 / 34卷 / SUPPL_3期
关键词：
D O I：
10.1136/ijgc-2024-IGCS.59
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PR017
引用
收藏
页码：A45 / A46
页数：2
相关论文
共 50 条
  • [31] Inhibition of GAS6/AXL improves efficacy of HER2 inhibitor trastuzumab in uterine serous cancer
    Tankou, Joan
    Toboni, Michael
    Kuroki, Lindsay
    McCourt, Carolyn
    Hagemann, Andrea
    Thaker, Premal
    Powell, Matthew
    Khabele, Dineo
    Mutch, David
    Fuh, Katherine
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S190 - S190
  • [32] Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu
    Fader, Amanda N.
    Roque, Dana M.
    Siegel, Eric
    Buza, Natalia
    Hui, Pei
    Abdelghany, Osama
    Chambers, Setsuko K.
    Secord, Angeles Alvarez
    Havrilesky, Laura
    O'Malley, David M.
    Backes, Floor
    Nevadunsky, Nicole
    Edraki, Babak
    Pikaart, Dirk
    Lowery, William
    ElSahwi, Karim S.
    Celano, Paul
    Bellone, Stefania
    Azodi, Masoud
    Litkouhi, Babak
    Ratner, Elena
    Silasi, Dan-Arin
    Schwartz, Peter E.
    Santin, Alessandro D.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (20) : 2044 - +
  • [33] Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An update including survival
    Rober, NJ
    Leyland-Jones, B
    Asmar, L
    Belt, RJ
    Ilegbodu, D
    Loesch, DM
    Raju, RN
    Cobleigh, M
    Albain, KS
    Slamom, DJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 20S - 20S
  • [34] Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk or pertuzumab, trastuzumab, and hyaluronidase-zzxf in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma (NRG-GY026)
    Erickson, Britt Kristina
    Enserro, Danielle
    Lankes, Heather A.
    Dockery, Lauren E.
    Ghamande, Sharad A.
    Oliver, Matthew T.
    Gressel, Gregory M.
    Castellano, Tara
    Ratner, Elena
    Deery, Amy
    Bishop, Erin
    Bradford, Leslie Siriya
    Pepin, Jessica Thomes
    Burton, Elizabeth
    Blank, Stephanie V.
    Santin, Alessandro
    Havrilesky, Laura J.
    Aghajanian, Carol
    Fader, Amanda Nickles
    Powell, Matthew A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] Identifying the worst of the worst: HER2 positive early stage uterine papillary serous carcinoma
    Rossi, Emma C.
    GYNECOLOGIC ONCOLOGY, 2020, 159 (01) : 1 - 2
  • [36] Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma
    Safran, Howard
    DiPetrillo, Thomas
    Akerman, Paul
    Ng, Thomas
    Evans, Devon
    Steinhoff, Margaret
    Benton, David
    Purviance, John
    Goldstein, Lisa
    Tantravahi, Umadevi
    Kennedy, Teresa
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 67 (02): : 405 - 409
  • [37] RANDOMIZED PHASE II TRIAL OF CARBOPLATIN-PACLITAXEL COMPARED TO CARBOPLATIN-PACLITAXEL-TRASTUZUMAB IN ADVANCED (STAGE III-IV) OR RECURRENT UTERINE SEROUS CARCINOMA: RESULTS OF INTERIM ANALYSIS (NCT01367002)
    Santin, A. D.
    Fader, A. N.
    Siegel, E.
    Buza, N.
    Pei, H.
    Abdelghany, O.
    Silasi, D. A.
    Chambers, S.
    Secord, A.
    Havrilesky, L.
    O'Malley, D. M.
    Nevadunsky, N.
    Edraki, B.
    Pikaart, D.
    Lowery, W.
    ElSahwi, K.
    Roque, D.
    Schwartz, P.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 873 - 874
  • [38] Inhibition of GAS6/AXL improves efficacy of HER2 inhibitor trastuzumab in uterine serous cancer.
    Tankou, Joan
    Toboni, Michael
    Noia, Hollie
    Oplt, Alyssa
    Wilke, Daniel
    Khabele, Dineo
    Kuroki, Lindsay
    Hagemann, Andrea
    McCourt, Carolyn
    Thaker, Premal
    Mutch, David
    Powell, Matthew
    Fuh, Katherine
    CLINICAL CANCER RESEARCH, 2021, 27 (03)
  • [39] Expression of Her2/neu receptor in carcinoma gallbladder correlates significantly with advanced tumor stage
    Ashai, Farzana
    Ashraf, Aadil
    Rashid, Arshad
    Banday, Bilal Musharaf
    Bhalla, Sunita
    Dhawan, Shashi
    INTERNATIONAL JOURNAL OF HEPATOBILIARY AND PANCREATIC DISEASES, 2015, 5 (02): : 86 - 91
  • [40] PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas (vol 113, pg 1020, 2015)
    Black, Jonathan D.
    Lopez, Salvatore
    Cocco, Emiliano
    Bellone, Stefania
    Altwerger, Gary
    Schwab, Carlton L.
    English, Diana P.
    Bonazzoli, Elena
    Predolini, Federica
    Ferrari, Francesca
    Ratner, Elena
    Silasi, Dan-Arin
    Azodi, Masoud
    Schwartz, Peter E.
    Santin, Alessandro D.
    BRITISH JOURNAL OF CANCER, 2015, 113 (11) : 1641 - 1641
12345